<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Helwick, Caroline</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Nissen, Steven</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Torcetrapib Fails to Meet Expectations</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">17-20</style></pages><abstract><style  face="normal" font="default" size="100%">Increased levels of high-density lipoprotein cholesterol decrease the risk of cardiovascular disease. Torcetrapib, a cholesteryl-ester-transfer protein inhibitor, has a potent effect on increasing HDL-C levels that was hoped would translate into the halting or reversal of atherosclerosis. The results from three clinical trials of torcetrapib are discussed in this article.</style></abstract><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">7</style></volume></record></records></xml>